公开(公告)号：WO2017223457A1

公开(公告)日：2017-12-28

申请号：PCT/US2017/039011

申请日：2017-06-23

Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

Inventor： POURQUIE, Olivier ,  CHAL, Jerome

IPC: C12N5/07 ,  C12N5/071 ,  C12Q1/02 ,  C12Q1/68 ,  A61K35/35 ,  A61P5/00

CPC classification number: C12N5/0653 ,  A61K35/35 ,  A61K49/0008 ,  A61P5/00 ,  C12N2500/25 ,  C12N2501/105 ,  C12N2501/115 ,  C12N2501/12 ,  C12N2501/155 ,  C12N2501/385 ,  C12N2501/39 ,  C12N2501/395 ,  C12N2501/415 ,  C12N2506/02 ,  C12N2506/45 ,  C12N2533/54 ,  C12Q1/6881 ,  C12Q2600/158 ,  G01N33/5023 ,  G01N33/5041 ,  G01N33/5044 ,  G01N2800/044

Abstract: A population of Brown adipose tissue (BAT) cells generated from embryonic stem cells (ES) or induced pluripotent stem cells (iPS), called iBAT, the use thereof, methods to obtain iBAT by directed differentiation of ES/iPS, and media compositions to obtain iBAT.

Abstract translation: 从胚胎干细胞（ES）或诱导性多能干细胞（iPS）产生的称为iBAT的棕色脂肪组织（BAT）细胞群，其用途，通过定向分化获得iBAT的方法 ES / iPS和媒体组合来获得iBAT。

公开(公告)号：WO2018031933A2

公开(公告)日：2018-02-15

申请号：PCT/US2017/046593

申请日：2017-08-11

Applicant: UNIVERSITY OF MASSACHUSETTS

Inventor： KHVOROVA, Anastasia ,  NIKAN, Mehran ,  HASSLER, Matthew ,  OSBORN, Maire ,  HARASZTI, Reka ,  COLES, Andrew ,  TURANOV, Anton ,  ARONIN, Neil ,  BISCANS, Annabelle

IPC: A61K48/00 ,  C07H21/04

CPC classification number: C12N15/113 ,  A61K9/0019 ,  A61K31/7088 ,  A61K47/54 ,  A61K47/543 ,  A61K47/549 ,  A61K47/551 ,  A61K47/554 ,  A61P1/00 ,  A61P1/16 ,  A61P5/00 ,  A61P9/00 ,  A61P11/00 ,  A61P13/12 ,  C07H21/00 ,  C07H21/02 ,  C07H21/04 ,  C12N15/111 ,  C12N2310/14 ,  C12N2310/312 ,  C12N2310/315 ,  C12N2310/346 ,  C12N2310/351 ,  C12N2310/3515 ,  C12N2320/32 ,  C12N2310/321 ,  C12N2310/3521 ,  C12N2310/322 ,  C12N2310/3533

Abstract: Provided herein are conjugated oligonucleotides that are characterized by efficient and specific tissue distribution.

Abstract translation: 本文提供了以有效和特异性组织分布为特征的缀合寡核苷酸。

公开(公告)号：WO2016161285A1

公开(公告)日：2016-10-06

申请号：PCT/US2016/025553

申请日：2016-04-01

Applicant: AOBIOME LLC

Inventor： WEISS, Larry ,  WHITLOCK, David, R.

IPC: A61K8/99 ,  A61K8/00 ,  A61K31/00 ,  A61K31/19 ,  A61K45/00

CPC classification number: A61K35/74 ,  A61K8/99 ,  A61K9/0014 ,  A61K31/04 ,  A61K31/20 ,  A61K31/201 ,  A61K31/202 ,  A61K35/744 ,  A61K35/745 ,  A61K35/747 ,  A61K45/06 ,  A61K2800/10 ,  A61K2800/522 ,  A61P5/00 ,  A61P9/00 ,  A61P11/00 ,  A61P13/12 ,  A61P17/00 ,  A61P17/06 ,  A61P17/10 ,  A61P25/00 ,  A61P29/00 ,  A61Q19/00 ,  C12P13/008 ,  C12Q1/04 ,  A61K2300/00

Abstract: This disclosure provides compositions containing ammonia oxidizing bacteria and methods of use, including treatment of disorders related to inflammation. Also provided are compositions containing nitro-fatty acids and nitro-hydrocarbons and methods of generating same using ammonia oxidizing bacteria.

Abstract translation: 本公开提供了含有氨氧化细菌和使用方法的组合物，包括治疗与炎症相关的疾病。 还提供了含有硝基 - 脂肪酸和硝基烃的组合物以及使用氨氧化细菌产生它们的方法。

公开(公告)号：WO2016054406A1

公开(公告)日：2016-04-07

申请号：PCT/US2015/053545

申请日：2015-10-01

Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC. ,  THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES ,  YU, Paul, B. ,  CUNY, Gregory, D. ,  MOHEDAS, Agustin, H. ,  LEE, Arthur ,  UNIVERSITY OF HOUSTON SYSTEM

Inventor： YU, Paul, B. ,  CUNY, Gregory, D. ,  MOHEDAS, Agustin, H. ,  LEE, Arthur

IPC: C07D401/14 ,  C07D417/14 ,  C07D221/22 ,  C07D403/02 ,  A61K31/551 ,  C07D213/02 ,  C07D401/04 ,  C07D409/04 ,  A61K31/44

CPC classification number: C07D401/14 ,  A61K31/44 ,  A61K31/551 ,  A61P3/00 ,  A61P5/00 ,  A61P9/00 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  C07D213/02 ,  C07D213/38 ,  C07D213/61 ,  C07D213/64 ,  C07D213/73 ,  C07D213/74 ,  C07D221/22 ,  C07D401/04 ,  C07D403/02 ,  C07D405/04 ,  C07D409/04 ,  C07D417/14 ,  C07D487/04

Abstract: The present invention provides small molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate ceil growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascujar disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to reduce circulating levels of ApoB- i 00 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.

Abstract translation: 本发明提供了BMP信号的小分子抑制剂以及抑制BMP信号传导的组合物和方法。 这些化合物和组合物可用于调节细胞生长，分化，增殖和凋亡，因此可用于治疗与BMP信号相关的疾病或病症，包括炎症，心血管疾病，血液病，癌症和骨骼疾病，如 以及调节细胞分化和/或增殖。 这些化合物和组合物也可用于降低ApoB-00或LDL的循环水平，并治疗或预防获得性或先天性高胆固醇血症或高脂蛋白血症; 与脂质吸收或代谢缺陷相关的疾病，病症或综合征; 或由高脂血症引起的疾病，病症或综合征。

公开(公告)号：WO2018206959A1

公开(公告)日：2018-11-15

申请号：PCT/GB2018/051259

申请日：2018-05-10

Applicant: BENEVOLENTAI BIO LIMITED

Inventor： SHEPPARD, David ,  ANDREOTTI, Daniele ,  SABBATINI, Fabio Maria

IPC: A61K31/506 ,  A61P25/00 ,  A61P15/00 ,  A61P3/00 ,  A61P43/00 ,  A61P5/00

CPC classification number: A61K31/506 ,  A61P3/00 ,  A61P5/00 ,  A61P25/00 ,  A61P43/00

Abstract: The present invention relates to orexin receptor antagonists, pharmaceutical compositi comprising the antagonists, methods of making the antagonists, their use for the modulation of the orexin receptor, and to use of the antagonists as medicaments, in particular for treating diseases, disorders, or conditions mediated by orexin receptor activity. More specifically, there is provided a compound of Formula (I) including salts thereof, polymorphs, and isomers thereof (including optical, geometric and tautomeric isomers) as defined herein and isotopically-labelled compounds of Formula (I).

公开(公告)号：WO2018203048A1

公开(公告)日：2018-11-08

申请号：PCT/GB2018/051165

申请日：2018-05-01

Applicant: MEDHERANT LIMITED

Inventor： HADDLETON, David

IPC: A61K9/70 ,  A61K9/00 ,  A61K47/34 ,  A61K31/167 ,  A61K31/192 ,  A61K31/196 ,  A61K31/465 ,  A61K31/496 ,  A61K31/522 ,  A61K31/573 ,  A61K31/60 ,  A61K31/616 ,  A61P31/04 ,  A61P31/10 ,  A61P17/02 ,  A61P3/00 ,  A61P25/16 ,  A61P25/20 ,  A61P25/28 ,  A61P29/00 ,  A61P35/00 ,  A61P25/26 ,  A61P25/34 ,  A61P25/18 ,  A61P31/12 ,  A61P5/00 ,  A61P9/12

CPC classification number: A61K31/167 ,  A61K9/0014 ,  A61K9/7069 ,  A61K31/192 ,  A61K31/196 ,  A61K31/465 ,  A61K31/496 ,  A61K31/522 ,  A61K31/573 ,  A61K31/60 ,  A61K31/616 ,  A61K47/34 ,  A61P3/00 ,  A61P5/00 ,  A61P9/12 ,  A61P17/02 ,  A61P25/16 ,  A61P25/18 ,  A61P25/20 ,  A61P25/26 ,  A61P25/28 ,  A61P25/34 ,  A61P29/00 ,  A61P31/04 ,  A61P31/10 ,  A61P31/12 ,  A61P35/00

Abstract: The invention relates to a silyl-containing polymer that is used, together with a tackifying resin to form an adhesive composition capable of storing and delivering drugs to the skin of a user. Typically the composition is formed into a patch which shows excellent adhesion to the skin even when drugs and other additives are dissolved into the composition.

公开(公告)号：WO2011088188A1

公开(公告)日：2011-07-21

申请号：PCT/US2011/021100

申请日：2011-01-13

Applicant: NOVARTIS AG ,  HU, Qi-Ying ,  KSANDER, Gary ,  MEREDITH, Erik ,  MONOVICH, Lauren G. ,  PAPILLON, Julien ,  SCHUMACHER, Christoph

Inventor： HU, Qi-Ying ,  KSANDER, Gary ,  MEREDITH, Erik ,  MONOVICH, Lauren G. ,  PAPILLON, Julien ,  SCHUMACHER, Christoph

IPC: A61P5/00 ,  A61K31/4188 ,  A61K31/55

CPC classification number: C07F9/6506 ,  A61K31/4188 ,  A61K31/55 ,  A61P5/00 ,  C07D487/04

Abstract: The present invention relates to a method of treating a disease or disorder characterised by increased stress hormone levels and/or decreased androgen hormone levels in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I): wherein n is 1 or 3; R is hydrogen or --C(O)N(R a )(R b ) wherein R a and R b are independently --(C 1 -C 4 ) alkyl, or --(C 1 -C 4 ) alkyl-(C 5 -C 7 ) aryl, wherein each of R a and R b is optionally substituted by --(C 1 -C 4 ) alkoxy; R 1 , R 2 , and R 3 , are independently hydrogen, halogen, cyano or --(C 6 -C 10 ) aryl, wherein said --(C 6 -C 10 ) aryl is optionally substituted by halogen, with the proviso that no more than one of R 1 , R 2 , and R 3 is hydrogen; and R 4 and R 5 are hydrogen; or a pharmaceutically acceptable salt thereof.

Abstract translation: 本发明涉及治疗受试者特征为增加的应激激素水平和/或降低雄激素激素水平的疾病或病症的方法，包括向受试者施用治疗有效量的由式（I）表示的化合物：其中 n为1或3; 其中R a和R b独立地为 - （C 1 -C 4）烷基或 - （C 1 -C 4）烷基 - （C 5 -C 7）芳基），其中R 1为氢或-C（O）N（R a） Ra和Rb中的每一个任选被 - （C 1 -C 4）烷氧基取代; R 1，R 2和R 3独立地为氢，卤素，氰基或 - （C 6 -C 10）芳基，其中所述 - （C 6 -C 10）芳基任选被卤素取代，条件是不超过1个 ，R2和R3是氢; R4和R5是氢; 或其药学上可接受的盐。

公开(公告)号：WO2018068120A1

公开(公告)日：2018-04-19

申请号：PCT/BR2017/050314

申请日：2017-10-11

Applicant: PROTEIMAX BIOTECNOLOGIA LTDA ,  REMER CONSULTORES ASSESSORIA EMPRESARIAL LTDA

Inventor： REMER, Ricardo Amaral ,  HEIMANN, Andrea Sterman

IPC: A61K38/08 ,  A61P25/08 ,  A61P3/04 ,  A61P3/10 ,  A61P5/00 ,  A61P3/14 ,  A61P1/00 ,  A61P5/14 ,  A61P19/10 ,  A61P43/00

CPC classification number: A61K38/08 ,  A61P1/00 ,  A61P3/04 ,  A61P3/10 ,  A61P3/14 ,  A61P5/00 ,  A61P5/14 ,  A61P19/10 ,  A61P25/08 ,  A61P43/00

Abstract: A presente invenção situa-se nos campos da química, farmácia, biotecnologia e medicina. Mais especificamente, a presente invenção descreve um composto, seu uso, um intermediário de síntese na preparação de compostos de interesse farmacêutico, uso do composto para preparar um ligante de interesse diagnóstico e/ou terapêutico, o uso para preparar medicamento modulador do metabolismo ou um medicamento neuromodulador, uma composição farmacêutica contendo o referido composto peptídico e um método terapêutico. O composto da invenção se liga a e/ou modula a atividade de receptores canabinóides (CB), especialmente CB1 e/ou CB2, e/ou receptores muscarínicos e se mostrou surpreendentemente útil para a modulação dos respectivos sistemas. A composição da invenção é útil para a modulação de função metabólica e/ou para neuromodulação. Em uma concretização, a administração oral do composto da invenção a um mamífero proporciona excelente resultado neuroprotetor e anticonvulsivante, que entre outras vantagens e efeitos técnicos não possui os inconvenientes decorrentes do uso de substâncias canabinóides – como o Canabidiol - e proporciona efeito terapêutico mais intenso, em menor dosagem e com menos efeito colaterais.

Abstract translation: 本发明属于化学，制药，生物技术和医学领域。 更具体地，本发明MAKE-HANDS描述了一种化合物，它的使用，中间A S河＆iacute; ntese在制备MAKE-HANDS，兴趣药剂师＆ecirc的化合物; utico，使用用于制备感兴趣DIAGN＆oacute的配位体的化合物; 脓毒性和/或疗法＆ecirc; utico，使用用于制备代谢调节剂的药物或神经调节药物，一个补充手中，药用＆ecirc;含Utica的所述化合物的肽基及iacute;医师且m＆eacute;所有疗法＆ecirc; utico。 本发明MAKE-HANDS所述的化合物，所述结合和/或调节受体活性canabin＆oacute;集成开发环境（CB），特别是CB1和/或CB2，和/或muscar＆iacute受体; NICOS和令人惊讶＆uacute示出;用于调制MAKE-有用 他们各自的系统。 本发明的组合物是非 - 用于调节代谢功能和/或用于神经调节。 在实施例中MAKE-手中，，给药MAKE-HANDS，本发明＆ccedil的口服化合物;＆HAND到一个MAM＆iacute; FERO提供了极好的神经保护结果和抗惊厥药，其中其它的优点和效果T＆eacute之间; cnicos N'HAND具有所产生的缺点 使用SUBST＆ACIRC的; canabin趋势与oacute;集成开发环境 - 如大麻二酚 - 疗法＆效果，并提供ecirc; utico在更低的剂量和副作用少更加激烈。

公开(公告)号：WO2018032787A1

公开(公告)日：2018-02-22

申请号：PCT/CN2017/079873

申请日：2017-04-10

Applicant: 安源医药科技(上海)有限公司

Inventor： 李强 ,  陈思 ,  郑云程 ,  李子瑞 ,  马心鲁

IPC: C07K19/00 ,  C12N15/62 ,  A61K38/27 ,  A61P5/00

CPC classification number: A61K38/27 ,  A61P5/00 ,  C07K19/00 ,  C12N15/62

Abstract: 一种高糖基化人生长激素融合蛋白，其从N端到C端依次含有人生长激素(hGH)、柔性肽接头(L)、至少一个人绒毛膜促性腺激素β-亚基羧基末端刚性肽(CTP)和人免疫球蛋白Fc片段。一种高效制备上述融合蛋白的方法。上述融合蛋白比重组hGH具有更优的体内药效，延长的体内循环半衰期，给药频率大大降低且生物利用度提高；同时其生产过程也更简单、高效。

公开(公告)号：WO2013184216A1

公开(公告)日：2013-12-12

申请号：PCT/US2013/031673

申请日：2013-03-14

Applicant: AMUNIX OPERATING INC. ,  CLELAND, Jeffrey L. ,  BRIGHT, George M. ,  HUMPHRISS, Eric ,  SCHELLENBERGER, Volker ,  SILVERMAN, Joshua ,  STEMMER, Willem P. ,  WANG, Chia-Wei ,  GEETHING, Nathan ,  SPINK, Benjamin

Inventor： CLELAND, Jeffrey L. ,  BRIGHT, George M. ,  HUMPHRISS, Eric ,  SCHELLENBERGER, Volker ,  SILVERMAN, Joshua ,  STEMMER, Willem P. ,  WANG, Chia-Wei ,  GEETHING, Nathan ,  SPINK, Benjamin

IPC: A61K38/27 ,  A61K47/42 ,  A61P5/00

CPC classification number: C07K14/61 ,  A61K38/27 ,  A61P5/00 ,  C07K14/00 ,  G01N33/566

Abstract: The present invention concerns an improved therapeutic regimen for GHD therapy. In particular, the invention concerns methods for bolus dose administration of a human growth hormone- XTEN (hGH-XTEN) fusion protein.

Abstract translation: 本发明涉及用于GHD治疗的改进的治疗方案。 特别地，本发明涉及用于推注剂量施用人生长激素-XTEN（hGH-XTEN）融合蛋白的方法。